Pemafibrate & Telmisartan Reverse Fatty Liver, Study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Barcelona announced on April 22 2026 that its researchers showed a pemafibrate‑telmisartan combo slashed liver fat in mouse models of MASLD.
- Pemafibrate combined with telmisartan reduced liver fat and heart‑risk markers in preclinical tests, achieving the same benefit as higher doses of each drug alone.
- Marta Alegret led the cross‑institutional effort involving CIBEROBN and Uppsala University, highlighting a repurposing strategy that fast‑tracks a safe, low‑cost therapy for the one‑in‑three‑adult MASLD epidemic.
Why it matters: Patients with MASLD, roughly 33% of adults, gain a promising, low‑cost therapy that eases health‑system burden, reduces cardiovascular mortality, and offers pharma firms a fast‑track repurposing opportunity.
Ask SkimNews
